The agreement will initially focus on immunology disorders. It also gives UCB the option to engage Nodality to develop companion diagnostics for UCB’s compounds.
The terms of the agreement include an upfront payment, R&D funding, and success-based milestones if all applicable development, regulatory and commercialization milestones are achieved.
In addition, Nodality may be eligible for royalties on future diagnostic sales.
The details of the terms have not been disclosed.
Nodality CEO David Parkinson said based on their application of SCNP platform to malignant and autoimmune diseases, they will be able to add significant value to UCB’s drug development portfolio.